Atlas Trials

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

Clinical trial NCT03953833 · COMPLETED

Trial details

NCT number
NCT03953833
Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2019-04-01
Primary completion
2023-01-13
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.